Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Sidley Represents Immunovant in US$550 Million OfferingDecember 12, 2025The International Comparative Legal Guide to: Merger Control 2026December 11, 2025Sidley Ranked in Chambers Asia-Pacific 2026December 11, 2025Sidley Elects Partnership Class of 29 and Counsel Class of 15 Across Europe and U.S.December 11, 2025Court of Chancery Reaffirms High Bar for Challenging Advance Notice Bylaws, but Emphasizes the Importance of Clear DraftingDecember 10, 2025Sidley Represents Lido Advisors in Its Partnership With Stuart Chaussée & AssociatesDecember 10, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory